APEX-Agents · Management Consulting
World125_Task01_NA
APEX-Agents task World125_Task01_NA in AI Agents for Cross-Border Regulatory Review. Compare dual-harness agent runs across models, scores, and public traces.
Task prompt
What the agent was asked to do
Using the 2024 annual report, identify whether Impact Therapeutics sells primarily branded drugs. A company sells primarily branded drugs if the majority of drugs have launch dates within the last 7 years. Please use the BCG report to determine the average COGS as a % of revenue for competitors in Impact Therapeutics' segment, based on whether they sell primarily generic drugs, branded, or a mix. Round to the nearest %. In both the global and US geos, state whether Impact Therapeutics is above the segment average calculated from the data in the BCG report. Write your response as a reply to me here.
Published trajectories
Agent runs on this task
Curated dual-harness runs (parsed + original sandbox). Best scored run per model.
| Model | Harness | Score | Result | Links |
|---|---|---|---|---|
| Gemini 3.1 Pro | dual | 4/4 | Pass | Run detailsPublic trace |
| GPT-5.4 | dual | 4/4 | Pass | Run detailsPublic trace |
| GPT-5.4 mini | dual | 4/4 | Pass | Run detailsPublic trace |
| GPT-5.4 nano | dual | 4/4 | Pass | Run detailsPublic trace |
| GPT-5.5 | dual | 4/4 | Pass | Run detailsPublic trace |
Grading rubric
Rubric criteria
Runs are graded against these criteria. Open a run for model-specific verdicts.
States that Impact Therapeutic is a company that primarily sells branded drugs
States the average of COGS as a share of revenue for companies that primarily sell branded drugs is 23%
States that the global COGS as a share of revenue for Impact Therapeutics in 2024 is higher than the average of 23%
States that the US COGS as a share of revenue for Impact Therapeutics in 2024 is higher than the average of 23%